Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II bevacizumab + temozolomide in first-line metastatic uveal melanoma
2009-011751-46Phase 2Active
- Sponsor
- Institut Curie
- Start
- Jun 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and temozolomide in intraocular melanoma and choroidal melanoma, sponsored by Institut Curie. Primary endpoint: Progression-free survival at 6 months. Started Jun 2009; status: active.
02
Drugs
bevacizumabtemozolomide
03
Conditions
intraocular melanomachoroidal melanoma
Beyond the preview
Go deeper on 2009-011751-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011751-46.